ReNAgade Therapeutics to Present at the Evercore ISI 2024 Emerging Biotech Conference
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced that Amit D. Munshi, Chief Executive Officer, will virtually present at the Evercore ISI 2024 Emerging Biotech Conference on Thursday, February 29, 2024, at 9:35 a.m. ET.
A webcast of the event will be available in the "News" section of the Company's website at https://renagadetx.com/news/. A replay of the webcast will be archived on the Company's website for 90 days following the presentation date.
About ReNAgade Therapeutics
ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines.
To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.
ReNAgade Therapeutics?RNA Without Limits
For more information about the company, its technologies, and its leadership, visit www.renagadetx.com.
Fun88, a leading company in sports and entertainment, proudly announces its official title sponsorship with the Vizag Warriors for the Andhra Premier League (APL)....
KLab Inc., a leader in online mobile games, announced that its hit 3D action game Bleach: Brave Souls will be holding a Bleach: Brave Souls 9th Anniversary Bankai Live! on Sunday, July 14, 2024 from 18:30 (JST/UTC+9). See the original press release...
Azentio Software ("Azentio") - a leading end-to-end software company specializing in the BFSI sector, today announced the appointment of Aarthi Ramesh as Chief Customer Officer and Emma Foley as Chief Marketing Officer....
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...
Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) and Bel Group, today announced their long-term partnership to accelerate the food industry's transformation toward a more sustainable model. The companies will play a pivotal role in shaping...
